ELK1 and prostate cancer: The authors also confirmed that in other cell types (human gastric and prostate cancer cells), the same TFs exhibit differential results regarding CIP2A expression, since ETS1 downregulation (without ELK1 silencing) was adequate to decrease CIP2A [51].